Teck Reports Unaudited Third Quarter Results for 2025

(TSX:TECK.A),(TSX:TECK.B),(TSX:TECK-A),(TSX:TECK-B),(NYSE:TECK), VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited third quarter results for 2025. “The merger of equals between Teck and Anglo American announced this quarter is a unique opportunity to create a global leader in critical minerals and a […]

Teck Reports Unaudited Third Quarter Results for 2025

Teck Reports Unaudited Third Quarter Results for 2025 Merger of equals to create new global critical minerals champion and unlock substantial value GlobeNewswire October 22, 2025 VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited third quarter results for 2025. “The

Ubisoft Singapore Elevates Game Audio with Neumann Studio Monitors

Studio Blue sets new benchmarks for game audio production Ubisoft Singapore, a leading AAA game development studio in Southeast Asia, has recently outfitted its newly upgraded Studio Blue with Neumann studio monitors which belongs to Sennheiser Group to support advanced audio production workflows. As the first Dolby Atmos-enabled game development sound studio in Southeast Asia,

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

(Paris:IPN), Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults Ipsen to acquire

Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

(Paris:SAN), Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels

A2MAC1 and ZeBeyond partner to bring Simulation-First Powertrain Benchmarking to market

Munich, 22.10.2025 – A2MAC1 and ZeBeyond announce a strategic collaboration that introduces a simulation-first benchmarking platform for electric powertrains. The new approach enables OEMs and Tier 1 suppliers to validate vehicle efficiency and performance within days – compared to traditional teardown and dynamometer testing that can take more than a year. As automakers race to

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline GlobeNewswire October 22, 2025 Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in

A2MAC1 and ZeBeyond partner to bring Simulation-First Powertrain Benchmarking to market

A2MAC1 and ZeBeyond partner to bring Simulation-First Powertrain Benchmarking to market GlobeNewswire October 22, 2025 Munich, 22.10.2025 – A2MAC1 and ZeBeyond announce a strategic collaboration that introduces a simulation-first benchmarking platform for electric powertrains. The new approach enables OEMs and Tier 1 suppliers to validate vehicle efficiency and performance within days – compared to traditional

Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Press Release: Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study GlobeNewswire October 22, 2025 Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care

Terminus Modern Ballet Theatre Proudly Announces Launch of “Wabi Sabi Terminus” Series

Inaugural season kicks off with outdoor shows at the Atlanta Botanical Garden on October 30th; Performances will include several dates and locations Terminus Modern Ballet Theatre(TMBT) is proud to announce the revival of its signature public performance initiative, Wabi Sabi Terminus, which debutson October 30, 2025,at the AtlantaBotanical Garden. The show begins at 5:30 p.m.

Scroll to Top